Aubagio® delays onset of clinically definite MS, study
Aubagio® delays onset of clinically definite MS, study
Genzyme, a Sanofi company, announced today positive top-line results from the TOPIC trial for Aubagio (teriflunomide). The trial was designed to assess whether early initiation of Aubagio (teriflunomide) in patients who experienced their first neurological symptoms consistent with Clinically Isolated Syndrome (CIS) can prevent or delay conversion to clinically definite multiple sclerosis (CDMS)..... Read More - http://www.ms-uk.org/index.cfm/aubagio
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1468 Views
-
Last post by NHE
-
- 0 Replies
- 802 Views
-
Last post by NHE
-
- 0 Replies
- 2174 Views
-
Last post by frodo
-
- 0 Replies
- 1085 Views
-
Last post by NHE
-
- 1 Replies
- 1003 Views
-
Last post by jimmylegs
-
- 0 Replies
- 1312 Views
-
Last post by frodo
-
- 0 Replies
- 1566 Views
-
Last post by NHE
-
- 0 Replies
- 2000 Views
-
Last post by vesta
-
- 0 Replies
- 1607 Views
-
Last post by frodo